small molecule

ADQUEY

DIFAMILAST

Loss of exclusivityDecember 2036latest FDA-listed patent expiry

CompanyAcrotech Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand name	ADQUEY
Active ingredient	DIFAMILAST
Strength	1%
Dosage form	OINTMENT
Route	TOPICAL
Modality	Small molecule
FDA approval	February 2026
Marketing status	RX

Listed patents

Patent	Expires	Type
10588893	December 2036	substance, product
RE46792	March 2028	substance, product

Regulatory exclusivity

Code	Expires
NCE	February 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Acrotech Biopharma